BEVERLY, Mass. and TORONTO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that management will participate in the Oppenheimer Annual Healthcare Conference on Wednesday, March 17, 2021.
David Wolf, President and CEO of Hamilton Thorne Ltd., will represent the company at a virtual session to be held at 3:50 PM ET on March 17, 2021 and will be available for virtual one-on-one meetings during that day. To schedule a meeting with management, please contact your conference representative or email ir@hamiltonthorne.ltd.
About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd)
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Neither the TSX Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
| For more information, please contact: | ||
| David Wolf, President & CEO | Michael Bruns, CFO | Glen Akselrod |
| Hamilton Thorne Ltd. | Hamilton Thorne Ltd. | Bristol Investor Relations |
| 978-921-2050 | 978-921-2050 | 905-326-1888 |
| ir@hamiltonthorne.ltd | ir@hamiltonthorne.ltd | glen@bristolir.com |